Skip to main content

Table 3 Clinical characteristics of patients in association with CYP2D6

From: Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer

Characteristics

CYP2D6 Phenotype

N (97)

NM (48)

URM (32)

IM (16)

PM (1)

Tumor seize

 ≤ 2 cm

20 (20.61%)

3 (3.09%)

9 (8.57%)

0 (00%)

2 < size ≤ 5 cm

25 (25.77%)

25 (25.77%)

7 (6.66%)

0 (00%)

 > 5 cm

3 (3.09%)

4 (4.23%)

0 (00%)

1 (1.03%)

p-value

Ref

0.02

0.02

0.04

Grade

I

5 (4.76%)

1 (1.03%)

2 (2.06%)

0 (00%)

II

26 (26.80%)

30 (30.92%)

6 (6.18%)

0 (00%)

III

17 (17.52%)

1 (1.03%)

8 (7.61%)

1 (1.03%)

p-value

Ref

0.02

0.02

0.03

Recurrence

No recurrence

43 (44.32%)

31 (31.95%)

6 (6.18%)

0 (00%)

Locally

3 (2.85%)

0 (00%)

7 (6.66%)

1 (1.03%)

Metastatic

2 (1.90%)

1 (1.03%)

3 (2.85%)

0 (0%)

p-value

Ref

0.00

0.00

0.00

  1. CYP. _Cytochrome P450; URM _ ultra rapid metabolizer (CYP2D6); NM _ normal metabolizer (CYP2D6); IM _ intermediate metabolizer (CYP2D6) ; PM _ poor metabolizer (CYP2D6); Ref_reference gene